MedPath

Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors

Active, not recruiting
Conditions
Neuroendocrine Tumors
Carcinoma;Endocrine
Registration Number
NCT05168631
Lead Sponsor
Latin American Cooperative Oncology Group
Brief Summary

Multicenter retrospective longitudinal analytical study of patients with neuroendocrine tumors.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
88
Inclusion Criteria
  • Patients aged 18 years or older and with histologically confirmed neuroendocrine tumors;
  • Metastatic or inoperable disease;
  • Patients with clinical information about the therapies received, including exclusive palliative care.
Exclusion Criteria
  • Lack of data on survival outcomes and/or details on treatments received.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall survival2022
Secondary Outcome Measures
NameTimeMethod
Response rate per RECIST 1.1;2022
Progression-free survival by RECIST 1.1 from D1 of each treatment;2022
Symptom control time2022

Improvement of symptoms and/or stabilization of radiological disease in non-functioning ENT, at the physician's discretion

Incidence of complications of the disease and/or treatments, defined by adverse events2022

Trial Locations

Locations (7)

Ensino E Terapia de Inovacao Clinica Amo - Etica

🇧🇷

Salvador, Bahia, Brazil

Universidade Federal do Ceará/HOSPITAL UNIVERSITARIO WALTER CANTIDIO

🇧🇷

Fortaleza, Ceará, Brazil

Hospital Sírio Libanês Brasília

🇧🇷

Brasília, Distrito Federal, Brazil

Hospital Moinhos de Vento

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Fundacao Antonio Prudente - Ac Camargo Center

🇧🇷

São Paulo, Brazil

Hospital Alemão Oswaldo Cruz

🇧🇷

São Paulo, Brazil

Instituto Nacional de Enfermedades Neoplàsicas

🇵🇪

Surquillo, Peru

Ensino E Terapia de Inovacao Clinica Amo - Etica
🇧🇷Salvador, Bahia, Brazil

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.